Related Experiment Videos
DNA immunization with plasmids expressing hCGbeta-chimeras
Nadia Terrazzini1, Sólveig Hannesdóttir, Peter J Delves
1Department of Immunology and Molecular Pathology, University College London, 46 Cleveland Street, London W1T 4JF, UK.
Vaccine
|May 20, 2004
Summary
Enhancing human chorionic gonadotropin (hCG) immunogenicity via DNA immunization, with electroporation and protein boosts, increased hCG-specific antibodies. The primary limitation appears to be available protein quantity, not antigen form or T cell epitopes.
Area of Science:
- Immunology
- Vaccinology
- Molecular Biology
Background:
- Human chorionic gonadotropin (hCG) has applications in fertility control and cancer immunotherapy.
- Improving the immunogenicity of hCG is crucial for its vaccine and therapeutic potential.
Purpose of the Study:
- To explore DNA immunization strategies for enhancing hCG immunogenicity.
- To investigate methods for improving antibody responses against hCG.
Main Methods:
- DNA immunization using plasmids encoding hCGbeta, with and without electroporation.
- Protein boosts with hCG and adjuvant.
- Fusion proteins (hCGbeta-hFc, hCGbeta-C3d(3)) were tested to enhance T cell help and antigen presentation.
- Antibody levels were measured in immunized animals.
Main Results:
- Electroporation following DNA injection increased hCG-specific antibody levels.
- A protein boost further enhanced antibody responses.
- Membrane-bound or secreted hCGbeta forms yielded modest antibody responses.
- Fusion proteins did not significantly increase antibody levels; hCGbeta-C3d(3) fusion resulted in lower antibody levels.
Conclusions:
- The quantity of available protein is the main determinant of antibody levels in DNA immunization for hCG.
- Strategies like fusion proteins or enhanced antigen presentation did not overcome this limitation.
- Further research may focus on optimizing protein expression levels for improved hCG immunogenicity.